Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study

Zafirlukast and placebo were administered orally as individual agents to 20 dogs with atopic dermatitis. The pruritus was effectively reduced by at least 50% in 2/18 (11%) dogs that completed the trial with zafirlukast. Two dogs vomited after administration of the active drug.

Saved in:
Bibliographic Details
Published in:Canadian veterinary journal 2002-03, Vol.43 (3), p.203-206
Main Authors: Senter, D.A, Scott, D.W, Miller, W.H. Jr
Format: Article
Language:English
Subjects:
Administration, Oral
adverse effects
Animals
antagonists
atopy
Cross-Over Studies
dermatitis
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - veterinary
Dog Diseases - drug therapy
Dogs
drug effects
drug therapy
efficacy
Female
Indoles
Leukotriene Antagonists - therapeutic use
leukotrienes
Male
oral administration
Phenylcarbamates
pruritus
receptors
Scientific
Single-Blind Method
Sulfonamides
Tosyl Compounds - therapeutic use
treatment
Treatment Outcome
vomiting
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Zafirlukast and placebo were administered orally as individual agents to 20 dogs with atopic dermatitis. The pruritus was effectively reduced by at least 50% in 2/18 (11%) dogs that completed the trial with zafirlukast. Two dogs vomited after administration of the active drug.
ISSN:0008-5286